NextCure (NASDAQ:NXTC) Shares Down 1.1% – Should You Sell?

Shares of NextCure, Inc. (NASDAQ:NXTC) were down 1.1% during mid-day trading on Monday . The stock traded as low as $0.37 and last traded at $0.39. Approximately 50,769 shares were traded during trading, a decline of 45% from the average daily volume of 91,598 shares. The stock had previously closed at $0.39.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of NextCure in a report on Monday, March 17th.

NextCure Trading Down 1.1 %

The stock has a market capitalization of $10.81 million, a price-to-earnings ratio of -0.18 and a beta of 0.89. The firm has a 50-day moving average of $0.67 and a 200 day moving average of $0.98.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.07). Equities research analysts predict that NextCure, Inc. will post -1.87 EPS for the current fiscal year.

Institutional Trading of NextCure

Institutional investors have recently added to or reduced their stakes in the business. Tang Capital Management LLC raised its stake in shares of NextCure by 7.3% in the fourth quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock valued at $540,000 after purchasing an additional 47,614 shares in the last quarter. Citadel Advisors LLC lifted its position in NextCure by 40.6% during the 4th quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after buying an additional 22,724 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of NextCure by 27.9% during the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock valued at $400,000 after purchasing an additional 113,300 shares during the last quarter. Peapod Lane Capital LLC acquired a new stake in shares of NextCure in the 4th quarter valued at $311,000. Finally, Geode Capital Management LLC raised its holdings in NextCure by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock worth $307,000 after purchasing an additional 27,812 shares during the last quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.